clinical trial · NCT06400472
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company·phase1·recruiting·n = 575
Ovarian NeoplasmsEndometrial NeoplasmsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungTriple Negative Breast NeoplasmsPancreatic NeoplasmColorectal NeoplasmsSofe-MbevacizumabcarboplatinItraconazolepembrolizumab
brief summary
The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase 2 (dose expansion). The study will last up to approximately 5 years.
started
May 20, 2024
primary completion
Jun 1, 2029
completion
Jun 1, 2029
last updated
Oct 7, 2026
official title
A First-in-Human, Phase 1/2 Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Sofetabart Mipitecan (LY4170156), an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol